Articles with "gip glp" as a keyword



Photo from wikipedia

Subcutaneous GIP and GLP-2 inhibit nightly bone resorption in postmenopausal women: a preliminary study.

Sign Up to like & get
recommendations!
Published in 2021 at "Bone"

DOI: 10.1016/j.bone.2021.116065

Abstract: BACKGROUND Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-2 (GLP-2) are gut hormones secreted in response to food ingestion, and they have been suggested to regulate bone turnover. In humans, exogenous GIP and GLP-2 acutely inhibit… read more here.

Keywords: gip glp; gip; bone resorption;

Different mechanisms of GIP and GLP-1 action explain their different therapeutic efficacy in type 2 diabetes.

Sign Up to like & get
recommendations!
Published in 2020 at "Metabolism: clinical and experimental"

DOI: 10.1016/j.metabol.2020.154415

Abstract: BACKGROUND AND AIMS The reduced action of incretin hormones in type 2 diabetes (T2D) is mainly attributed to GIP insensitivity, but efficacy estimates of GIP and GLP-1 differ among studies, and the negligible effects of… read more here.

Keywords: t2d; type diabetes; gip; gip glp ... See more keywords

6989 Novel Use of Dual GIP/GLP-1 Receptor Agonist in HNF4A-MODY

Sign Up to like & get
recommendations!
Published in 2024 at "Journal of the Endocrine Society"

DOI: 10.1210/jendso/bvae163.869

Abstract: Abstract Disclosure: A. Mehdi: None. M.C. Foss de Freitas: Advisory Board Member; Self; PTC Pharmaceuticals. Other; Self; Scientific presenter in a symposium funded by Amryt Pharmaceuticals. C.L. Martin: None. B.E. Gregg: None. N. Nachawi: None.… read more here.

Keywords: hnf4a mody; mody; gip glp; receptor ... See more keywords

SAT-550 A Hidden Culprit: Insulinoma Masquerading as GLP-1 Agonist-Induced Hypoglycemia

Sign Up to like & get
recommendations!
Published in 2025 at "Journal of the Endocrine Society"

DOI: 10.1210/jendso/bvaf149.1081

Abstract: Abstract Disclosure: A.K. Jain: None. T. Amin: None. K. Chalasani: None. S.W. Holland: None. Introduction: Hypoglycemia in non-diabetic individuals is a diagnostic challenge that needs thorough evaluation to distinguish between endogenous and exogenous causes. Dual… read more here.

Keywords: glp agonist; insulin; gip glp; hypoglycemia ... See more keywords
Photo from wikipedia

80-LB: Tirzepatide, a Dual GIP/GLP-1 Receptor Agonist, Is Effective and Safe When Added to Basal Insulin for Treatment of Type 2 Diabetes (SURPASS-5)

Sign Up to like & get
recommendations!
Published in 2021 at "Diabetes"

DOI: 10.2337/db21-80-lb

Abstract: Tirzepatide (TZP) is a novel dual GIP/GLP-1 receptor agonist in development for type 2 diabetes (T2D). Efficacy and safety of TZP vs. placebo (PBO) was assessed in people with T2D as an add-on to titrated… read more here.

Keywords: company; lilly company; eli lilly; gip glp ... See more keywords

108-OR: Insulin Resistance Is Associated with Alterations in the Dynamics of Incretin Secretion

Sign Up to like & get
recommendations!
Published in 2024 at "Diabetes"

DOI: 10.2337/db24-108-or

Abstract: GIP and GLP-1 exert a fundamental role in glucose homeostasis, but it is still debated if modifications in GIP and GLP-1 secretion can affect the metabolic state, as well as their contribution to the dynamics… read more here.

Keywords: insulin; none; gip glp; secretion ... See more keywords

2155-LB: Hepatic BHMT Integrates GIP/GLP-1 Signaling to Ameliorate Metabolic Dysfunction through Coordinated Regulation of Lipid Metabolism and Fibrogenesis

Sign Up to like & get
recommendations!
Published in 2025 at "Diabetes"

DOI: 10.2337/db25-2155-lb

Abstract: Introduction and Objective: Metabolic dysfunction-associated steatohepatitis (MASH), a critical stage in NAFLD progression, lacks effective treatments. While GIP/GLP-1R dual agonists (GIP/GLP-1RA) show therapeutic potential, their mechanisms remain unclear. Our preclinical study identified serum BHMT downregulation… read more here.

Keywords: bhmt; glp 1ra; gip glp; hepatic bhmt ... See more keywords

Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity

Sign Up to like & get
recommendations!
Published in 2022 at "Frontiers in Endocrinology"

DOI: 10.3389/fendo.2022.1004044

Abstract: Incretin-based therapies with glucagon-like peptide-1 receptor agonists (GLP-1RA) are already established in the treatment of type 2 diabetes (T2D). The development of novel dual- or triple-receptor agonists that bind to the receptors not only for… read more here.

Keywords: gip glp; type diabetes; treatment; receptor ... See more keywords

Integrated Management of Cardiovascular–Renal–Hepatic–Metabolic Syndrome: Expanding Roles of SGLT2is, GLP-1RAs, and GIP/GLP-1RAs

Sign Up to like & get
recommendations!
Published in 2025 at "Biomedicines"

DOI: 10.3390/biomedicines13010135

Abstract: Cardiovascular–Kidney–Metabolic syndrome, introduced by the American Heart Association in 2023, represents a complex and interconnected spectrum of diseases driven by shared pathophysiological mechanisms. However, this framework notably excludes the liver—an organ fundamental to metabolic regulation.… read more here.

Keywords: glp 1ras; management; gip glp; syndrome ... See more keywords
Photo from academic.microsoft.com

Associations between Postprandial Gut Hormones and Markers of Bone Remodeling

Sign Up to like & get
recommendations!
Published in 2021 at "Nutrients"

DOI: 10.3390/nu13093197

Abstract: Gut-derived hormones have been suggested to play a role in bone homeostasis following food intake, although the associations are highly complex and not fully understood. In a randomized, two-day cross-over study on 14 healthy individuals,… read more here.

Keywords: gut; gut hormones; pyy; bone remodeling ... See more keywords

Tirzepatide - a dual GIP/GLP-1 receptor agonist - a new antidiabetic drug with potential metabolic activity in the treatment of type 2 diabetes.

Sign Up to like & get
recommendations!
Published in 2022 at "Endokrynologia Polska"

DOI: 10.5603/ep.a2022.0029

Abstract: The incretin hormones glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are responsible for up to 65% of postprandial insulin secretion. Tirzepatide, developed by Eli Lilly, is a dual GIP/GLP-1 receptor agonist in the… read more here.

Keywords: glp; dual gip; gip; gip glp ... See more keywords